Sentences with phrase «myeloma patients with»
Nearly 80 % of R / R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.
http://www.cancernetwork.com/
The combination of pomalidomide plus low - dose dexamethasone showed efficacy with high rates of disease control in relapsed or refractory multiple myeloma patients with severe renal impairment, according to the results of a phase II study.
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
The prognosis of myeloma patients with EMD behaves like other metastatic cancers and is extremely poor because its clinical course is very aggressive, Tse said.
Not exact matches
Empliciti will be used in combination with two other drugs to treat patients with multiple myeloma who have received one to three prior courses of medication.
The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma.
Diagnosed himself with myeloma in April 2015, Tony infuses All4Cure with an incredible sense of urgency to improve the prospects for cancer patients now and in the future.
THE PATIENT AS INNOVATOR With Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy Giusti of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co. — Report by Kia Kokalitcheva — Video: Patients Should Get Access to Their Health Data
The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval.
Analyzing a database of nearly 800 multiple myeloma patient samples, they discovered that 162 patients with low ADAR1 levels in their tumor cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.
«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.
Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.
Notably, the mechanism was clearly associated with poor outcome in patients with the blood cancer myeloma, where proteasome inhibitors are a mainstay of treatment.
The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.
«These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher disease and others with precursors for myeloma.
With multiple myeloma, most patients live four to seven years from their date of diagnosis, and most become resistant to chemotherapy drugs over time.
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.
Furthermore, the levels of Runx2 expression among a larger group of 351 newly diagnosed multiple myeloma patients were significantly higher in patients who had a high risk of early disease - related death, as compared with lower - risk patients.
As a patient's BMI increases, fat cells communicate with multiple myeloma cells, researchers found.
«In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome,» said Richardson, who is also the R.J. Corman professor at Harvard Medical School.
«Today, we have half a dozen drugs for multiple myeloma that can put patients into remission,» said Tomasson, who treats patients with multiple myeloma at Siteman Cancer Center at Barnes - Jewish Hospital and Washington University School of Medicine.
These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.
The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy.
In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.
For this analysis, 605 patients with newly diagnosed multiple myeloma and treated with continuous lenalidomide (brand name Revlimid) following autologous stem cell transplant were compared to 604 patients who were treated with placebo or no maintenance.
«Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma.»
«For patients diagnosed with MGUS, maintaining a healthy weight may be a way to prevent the progression to multiple myeloma, if further confirmed by clinical trials.»
Tse and the team analyzed the degree of expression of AF1q in 117 patients with multiple myeloma.
Approximately 25 percent of patients with multiple myeloma also simultaneously develop extramedullary disease.
A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen
«Minimal Residual Disease Status, Outcomes in Patients with Multiple Myeloma.»
«Effect of follow - up of MGUS on survival in patients with multiple myeloma.»
Trial # 3: Combined autophagy and proteasome inhibition: A phase 1 trial of HCQ and bortezomib in patients with relapsed / refractory myeloma
«Immunotherapy agent benefits patients with drug - resistant multiple myeloma.»
Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.
«We had about 140,000 patients diagnosed with lymphoma, leukemia or myeloma in America in 2009.
«Therapy shrinks tumors in patients with multiple myeloma.»
The method also is being evaluated in a clinical trial involving patients with multiple myeloma.
Pilar de la Puente, PhD (left), and Kareem Azab, PhD, of Washington University School of Medicine in St. Louis, have developed a screening tool that may predict quickly and more accurately the best treatments for individual patients with multiple myeloma.
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
In patients with the blood cancer multiple myeloma, an enzyme called thymidine phosphorylase sets off a chain reaction that leads to bone destruction, researchers report August 24 in Science Translational Medicine...
«And it has been instrumental in the prioritization of which experimental therapeutics should be tested in patients with multiple myeloma.»
«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»
One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse.
The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.
The researcher team from the University of Birmingham, New Cross and Heartlands Hospitals compared the cellular chemistry of bone marrow and blood samples taken from patients with myeloma, patients with MGUS and healthy volunteers.
Dr Daniel Tennant, who led the research at the University of Birmingham, said, «Our findings show that very few changes are required for a MGUS patient to progress to myeloma as we now know virtually all patients with myeloma evolve from MGUS.
All patients diagnosed with myeloma, a cancer of the blood - producing bone marrow, first develop a relatively benign condition called «monoclonal gammopathy of undetermined significance» or «MGUS».